United Therapeutics Corporation (UTHR)

Check out top investors' recommendation for UTHR
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
213.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Ch14.18 MAb, an antibody that is under Phase III clinical trails for the treatment of neuroblastoma; Beraprost 314d, which is under Phase II clinical trails for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trail for the treatment of metastatic brain cancer. Further, the company is involved in the early pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and PLacental eXpanded cells for the treatment of PAH; glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Liana Moussatos Wedbush Securities Inc. Buy   Nov 13, '17     213.00  Nov 13, '18  N/A 
Michael Yee RBC Capital Markets Sell   Aug 13, '17     105.00  Aug 13, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Apr 04, '17     229.00  Apr 04, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Feb 08, '17     229.00  Feb 08, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jan 05, '17     229.00  Jan 05, '18  N/A 
Matthew Kaplan Ladenburg Thalmann & Co. Buy   Oct 28, '16       Oct 28, '17  N/A 
Philip Nadeau Cowen And Company Buy   Sep 23, '16     144.00  Sep 23, '17  N/A 
Andrew Fein Chardan Capital Markets Buy   Feb 26, '16   123.80  175.00  Feb 26, '17  18.51% 
Liana Moussatos Wedbush Securities Inc. Buy   Feb 19, '16   127.32  244.00  Feb 19, '17  32.08% 
Ronnie Moas Bernstein Research Buy   Feb 10, '16   119.74    Feb 10, '17  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Oct 21, '15   123.35  244.00  Oct 21, '16  -8.36% 
Andrew Fein Chardan Capital Markets Buy   Oct 20, '15   122.91  175.00  Oct 20, '16  -5.23% 
Terence Flynn Goldman Sachs Sell   Jul 20, '15   177.51  95.00  Jul 20, '16  37.54% 
Liana Moussatos Wedbush Securities Inc. Buy   Apr 28, '15   163.31    Apr 28, '16  -27.94% 
Andrew Fein Chardan Capital Markets Buy   Feb 26, '15   155.58    Feb 26, '16  -19.76% 
Liana Moussatos Wedbush Securities Inc. Buy   Feb 20, '15   156.01    Feb 20, '16  -18.39% 
Liana Moussatos Wedbush Securities Inc. Buy   Dec 26, '14   131.95    Dec 26, '15  21.95% 
Ravi Mehrotra Credit Suisse Sell   Dec 11, '14   131.23    Dec 11, '15  -18.88% 
Andrew Fein Chardan Capital Markets Buy   Sep 02, '14   115.22    Sep 02, '15  25.51% 
Liana Moussatos Wedbush Securities Inc. Buy   Aug 29, '14   117.83  141.00  Aug 29, '15  36.20% 
< previous12